Effects of captopril and valsartan on ventricular remodeling and inflammatory cytokines after interventional therapy for AMI

Gong, Xiaona; Zhou, Rao-rao; Li, Qinhao

doi:10.3892/etm.2018.6626

Cited by 14 publications

(18 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Valsartan could promote a decrease in serum monocyte chemoattractant protein-1 (MCP-1). It also inhibited the expression of peroxisome proliferator–activated receptor γ (PPARγ) in monocytes [ 15 ], which stabilizes plaques, causes anti-vascular smooth muscle proliferation and anti-inflammation [ 16 , 17 ], prevents cardiovascular remodeling [ 16 ] and intimal hyperplasia [ 18 ], reduces the area of new membranes [ 13 ], reduces the incidence rate of in-stent restenosis, and reduces the revascularization rate [ 19 ]. The present study confirmed that the oral administration of valsartan from before surgery to 6-month follow-up could reduce the release of inflammatory factors, reduce restenosis, and improve clinical prognosis for patients with arteriosclerosis obliterans of the lower extremities who underwent stent implantation in the superficial femoral artery.…”

Section: Discussionmentioning

confidence: 99%

Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial

et al. 2020

View full text Add to dashboard Cite

Background The aim of this study was to further clarify the effects of valsartan on restenosis in patients with arteriosclerosis obliterans of the lower extremities. Material/Methods Patients with arteriosclerosis obliterans of the lower extremities undergoing continuous stent implantation in the superficial femoral artery were enrolled and randomly divided into an ARB group and a control group. Patients in the ARB group received valsartan orally in a single-blind manner and were followed up for 6 months. An evaluation was performed based on the criteria for clinical efficacies designed by the Committee of Vascular Disease, Chinese Association of Integrative Medicine. The total clinical effective rate was calculated, and ankle brachial index (ABI) of the patients was assessed. The concentrations of interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) were measured using enzyme-linked immunosorbent assay. The in-stent restenosis of patients was examined by angiography. Results One patient in the control group died due to acute cerebral hemorrhage 4 months after enrollment, and 1 patient was lost to follow-up due to acute myocardial infarction during follow-up 5 months after enrollment. Age, sex, Fontaine stage, and underlying diseases were comparable between the 2 groups. Hs-CRP (3.93±1.43) and IL-6 (11.26±2.29) levels were significant different in the ARB group compared with the control group. The postoperative follow-up showed that ABI was 0.98±0.20 in the ARB group and 0.62±0.48 in the control group. Conclusions Valsartan inhibited the increase in hs-CRP and IL-6 levels, improved clinical efficacies, increased ABI, and decreased the restenosis rate after the interventional therapy in patients with arteriosclerosis obliterans of the lower extremities.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Sample size was estimated based on previous studies involving early changes in cytokine titers. 10 , 11 The software SPSS, version 18.0 (IBM, Armonk, New York, USA), was used for statistical analysis. All p-values < 0.05 were considered statistically significant.…”

Section: Discussionmentioning

confidence: 99%

“…O tamanho amostral foi estimado com base em estudos anteriores envolvendo alterações precoces nos títulos de interleucinas. 10 , 11 O software SPSS, versão 18.0 (IBM, Armonk, Nova Iorque, EUA), foi utilizado para a análise estatística. Valores de p < 0,05 foram considerados estatisticamente significativos.…”

Section: Análise Estatísticaunclassified

Alterações Precoces nas Interleucinas Circulantes e no Risco Inflamatório Residual após Infarto Agudo do Miocárdio

Coste

França

Izar

et al. 2020

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Background: Patients with acute myocardial infarction may have a large infarcted area and ventricular dysfunction despite early thrombolysis and revascularization. Objective: To investigate the behavior of circulating cytokines in patients with ST-segment elevation myocardial infarction (STEMI) and their relationship with ventricular function. Methods: In the BATTLE-AMI (B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) trial, patients with STEMI were treated with a pharmacoinvasive strategy. The plasma levels of cytokines (IL-1β, IL-4, IL-6, IL-10, and IL-18) were tested using enzyme-linked immunosorbent assay (ELISA) at baseline and after 30 days. Infarcted mass and left ventricular ejection fraction (LVEF) were examined by 3-T cardiac magnetic resonance imaging. All p-values < 0.05 were considered statistically significant. Results: Compared to baseline, lower levels were detected for IL-1β (p = 0.028) and IL-18 (p < 0.0001) 30 days after STEMI, whereas higher levels were observed for IL-4 (p = 0.001) and IL-10 (p < 0.0001) at that time point. Conversely, no changes were detected for IL-6 levels (p = 0.63). The levels of high-sensitivity C-reactive protein and IL-6 correlated at baseline (rho = 0.45, p < 0.0001) and 30 days after STEMI (rho = 0.29, p = 0.009). At baseline, correlation between IL-6 levels and LVEF was also observed (rho =-0.50, p = 0.004). Conclusions: During the first month post-MI, we observed a marked improvement in the balance of pro-and anti-inflammatory cytokines, except for IL-6. These findings suggest residual inflammatory risk. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0

show abstract

“…After interventional therapy, oral aspirin enteric-coated tablets were taken at a dose of 100 mg once a day. Captopril (18 mg) and valsartan (80 mg) were taken once a day ( 10 ). The patients with AMI after treatment were followed up for one year.…”

Section: Methodsmentioning

confidence: 99%

Clinical diagnostic value of combined detection of IMA, D‑D and MCP‑1 in acute myocardial infarction

Ding

Yang

2021

Exp Ther Med

View full text Add to dashboard Cite

The aim of the study was to analyze the clinical value of the combined detection of ischemia-modified albumin (IMA), D-dimer (D-D) and monocyte chemoattractant protein-1 (MCP-1) in the diagnosis of acute myocardial infarction (AMI). Altogether 87 patients with AMI from January 2017 to January 2018 were enrolled in the AMI group, and 82 patients without coronary artery disease were included in the control group. The serum levels of IMA, D-D, MCP-1, cardiac troponin (CTnT) and high-sensitivity C-reactive protein (hs-CRP) in the two groups were detected by ELISA. The blood lipids of the two groups and the levels of IMA, D-D, MCP-1 after treatment were detected. The association between IMA, D-D, MCP-1, CTnT, hs-CRP and blood lipid in patients with AMI was analyzed. The values of IMA, D-D, and MCP-1 alone and combined in the diagnosis of AMI were analyzed by ROC curve. The levels of IMA, D-D, MCP-1, CTnT and hs-CRP in the AMI group were significantly higher than those in the control group (P<0.05). The levels of IMA, D-D and MCP-1 in the patients with poor prognosis were significantly higher than those of the good prognosis group (P<0.05). The changes of IMA, D-D and MCP-1 levels were positively correlated with the levels of CTT and hs-CRP (P<0.05). The AUC, specificity and sensitivity of patients with AMI diagnosed with MCP-1 alone were 0.8084, 81.61 and 69.51%, respectively. Those of patients diagnosed by D-D were 0.7302, 59.77 and 81.71%, those of patients diagnosed by IMA alone were 0.7289, 58.62 and 80.49%, and those of patients detected by the combination of MCP-1, D-D and IMA were 0.9047, 58.62 and 93.90%. In conclusion, the levels of IMA, D-D and MCP-1 in AMI patients are higher than those in the control group. The levels of IMA, D-D and MCP-1 were positively correlated with CTnT and hs-CRP levels in AMI patients. Combined detection of IMA, D-D, and MCP-1 can improve the accuracy.

show abstract

Effects of captopril and valsartan on ventricular remodeling and inflammatory cytokines after interventional therapy for AMI

Cited by 14 publications

References 18 publications

Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial

Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial

Alterações Precoces nas Interleucinas Circulantes e no Risco Inflamatório Residual após Infarto Agudo do Miocárdio

Clinical diagnostic value of combined detection of IMA, D‑D and MCP‑1 in acute myocardial infarction

Contact Info

Product

Resources

About